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Background: Cucurbitacin’s are dietary compounds that have been shown to cause 
anti-tumour, anti-inflammatory and anti-atherosclerotic activities. Mechanisms of 
action include dysregulation of the actin cytoskeleton and disruption of integrin 
function. Integrin outside-in signalling and cytoskeletal rearrangements are important 
for stable thrombus formation and clot retraction after platelet adhesion at the site 
of vessel damage. 
Aims: To identify the effect of cucurbitacin’s B, E and I on platelet function and 
thrombus formation. Methods: Human washed platelets, platelet rich plasma and 
whole blood in vitro platelet function assays were used including real time and end 
point platelet aggregation, platelet adhesion assay with DiOC6 and phalloidin staining, 
thrombus formation, flow cytometry and western blots to determine actin 
polymerisation activity and integrin function.  
Results: Anti-platelet and anti-thrombotic effects following treatment with 
cucurbitacin’s B, E and I were observed. Treatment of platelets with cucurbitacin B, E 
or I lead to reduction of platelet aggregation and fibrinogen binding following 
stimulation with ADP and collagen. Cucurbitacin B, E and were found to inhibit other 
integrin mediated events, including adhesion and spreading on adhesive surfaces such 
as fibrinogen. Additional investigation of cytoskeletal dynamics found treatment with 
cucurbitacin’s B, E and I increased actin polymerisation and myosin light chain 
phosphorylation which has been shown to disrupt integrin activation and platelet 
spreading.  Treatment with cucurbitacins was also found to disrupt stable thrombus 
formation, with an increase in the formation of unstable thrombi and a reduction in 
thrombus density compared to control.  
Conclusions: Cucurbitacins have anti-platelet and anti-thrombotic activity, which 









Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality 
in the world (Clark, 2013). Types of conditions covered by the term CVD include 
coronary artery disease, stroke, atherosclerosis, congenital heart disease, peripheral 
arterial disease, myocardial infarction (MI), deep venous thrombosis, pulmonary 
embolism and many other conditions linking to the cardiovascular system. The 
activation of blood platelets and aggregation is linked to the development of 
atherosclerosis, formation of blood clots and blockage of arteries. Platelet activation 
is essential for haemostasis, which is the binding of platelets to damaged blood vessels 
followed by aggregation and thrombus formation, preventing excess bleeding. 
However, platelet activation is also one of the main pathophysiology’s of 
atherosclerotic plaque formation, promoting the formation of a thrombus at site of a 
plaque rupture consequently leading to a myocardial infarction. (Thomas and Storey, 
2015).  
There are a number of anti-platelet drugs used for the treatment of CVD, including 
aspirin and clopidogrel. However, these drugs are associated with several  side effects 
in  patients, some of which are potentially life threatening such as excessive bleeding 
(Guthrie, 2011). Additionally, certain patients show resistance to anti-platelet drugs 
(Algra, 2013). For this reason, safer more effacious anti-platelet drugs that target 
different mechanisms are needed for the prevention and treatment of CVD. It’s been 
found that increased level of inflammation in the blood is what accelerates many 
diseases including CVD. Oxidative stress triggers elevated levels of inflammation, 
certain antioxidants found in fruits, vegetables and dietary supplements have been 
linked to the slowing of the progression of CVD (O’Kennedy et al., 2017). Cucurbitacins 
are dietary compounds which are found in the plants of family known as 
Cucurbitaceae. They have been known to show anti-inflammatory (Yuan et al., 2006) 
and antitumor activity (Alghasham, 2013) as well as anti-atherosclerotic activity 
(Bernard and Olayinka, 2010). Therefore, it is important to investigate the anti-
platelet properties of cucurbitacins due to the increasing incidence of cardiovascular 
disease, the negative effects that current antiplatelet therapies produce and the 




Platelets are anuclear cells with a diameter of approximately 3-4 µm and an average 
life span of 8-10 days. Platelets originate from bone-marrow megakaryocytes and 
circulate within the vascular system (Hou et al., 2015). They are discoid in shape and 
are encased by a plasma membrane which contain glycoproteins (GP) such as GPIa, 
GPIb and GPIIb/IIIa (Minors, 2007). Platelets contain messenger RNA (mRNA) so can 
synthesise a small number of proteins, but do not contain a nucleus which means they 
do not contain DNA  (Italiano Jr and Shivdasani, 2003). The schematic drawing of a 
platelet in figure 1 shows the contents of platelets, containing mitochondria, a 
canalicular system and specialised secretory granules. These include alpha, dense and 
lysosomal granules with each containing many pre-formed megakaryocyte-derived 
molecules. Granule secretion supports platelet activation and thrombus formation. 
 
α- Granules contain different mediators including chemokines such as CXCL4 (PF4), 
coagulant/anticoagulant factors such as factor V, factor IX which are important for 
secondary haemostasis but also anti-thrombin which cleaves clotting factors in both 
intrinsic and extrinsic pathways (pathways of coagulation) (Blair and Flaumenhaft, 
2009). They contain adhesion proteins like fibrinogen, fibronectin, von Willebrand 
Figure 1: Schematic drawing of a platelet Figure adapted from (Fitch-Tewfik and 
Flaumenhaft, 2013). Detailing contents of a platelet, with the small size each 
platelet contains surface receptors, a canalicular system, lysosomes, α-granules, 




factor (vWF) which main roles include contribution to platelet-endothelial and 
platelet-platelet adhesion through the formation of cross-bridges, P-selectin – a 
glycoprotein also found in the granules are translocated from the granules to the 
platelet surface following platelet activation which allows for the platelets to interact 
with endothelial cells, monocytes, neutrophils and lymphocytes. They also mediate 
platelet and neutrophil rolling on activated endothelial cells (Fitch-Tewfik and 
Flaumenhaft, 2013) and growth factors such as epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), vascular endothelium growth factor (VEGF) 
and others. They also contain approximately one-half to two-thirds of αIIbβ3 in a 
resting α-granule membranes although they are also found on platelet plasma 
membrane (Blair and Flaumenhaft, 2009). Dense granules contain cations such as 
calcium (Ca2+) and magnesium (Mg2+), nucleotides such as adenosine diphosphate 
(ADP) – an important agonist for platelet aggregation and ATP, serotonin and 
histamine (Sonmez and Sonmez, 2017). Finally, lysosomal granules include proteases 
such as cathepsin and glycohydrolase which are the lysosomes cargo and the 
lysosomes express CD63 - markers for platelet activation (Polasek, 2005). 
Platelets circulate in the vascular system in a quiescent state, inactivated by soluble 
mediators released by the endothelium including prostacyclin and nitric oxide (NO). 
These inhibit the activation and aggregation of platelets (Thomas and Storey, 2015).  
2.1.1 Platelet adhesion 
Following injury to vessel wall, platelets attach to subendothelial matrix proteins such 
as collagens, which are exposed to the blood. Plasma vWF is released from platelets, 
endothelial cells and megakaryocytes and binds to collagen forming a bridge between 
collagen and platelets.  In high shear stress conditions GPIbα-IX-V- the VWF receptor 
found on platelets, initiates the platelet adhesion to the injured site via binding of 
vWF. This GPIbα-VWF interaction is important for the tethering of circulating platelets 
to the vessel wall and slowing down the platelets so that GPVI can bind to collagen 
(Induruwa et al., 2018). This interaction and the integrin α2β1 binding to collagen 
initiates platelet signalling events which elicit platelet activation. In addition to GPIbα, 
the binding of other platelet integrin’s to their ligands on the extracellular vessel 
matrix consequently mediates stable adhesion. These include integrin αIIbβ3 to 
fibrinogen/fibrin and fibronectin (Ni and Freedman, 2003). In regions of low shear 
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stress such as veins, these interactions can directly trigger platelet adhesion (Bledzka 
et al., 2013).  
2.1.2 Platelet activation  
The interaction and binding of platelet surface receptors, to their ligands (e.g. 
collagen, fibronectin) can induce platelet activation (Berndt et al., 2014). Activation of 
agonists leads to an increase in cytosolic calcium, which is essential for platelet 
activation. This occurs through the activation of phospholipase C (PLC) which 
hydrolyses Phosphatidylinositol 4,5-bisphosphate (PIP2) to Inositol trisphosphate 
(IP3) and diacylglycerol (DAG). IP3 and DAG are secondary messengers which result in  
intracellular calcium release and activation of protein kinase c (PKC) respectively, 
which are important mediators of several platelet processes including  granule 
secretion (Stalker et al., 2012). The release of platelet granules amplifies the activation 
process to support additional platelets to be activated from a further distance. In 
addition to granule release, thromboxane (Tx) is generated and released and both 
ADP and Tx are secondary mediators of platelet activation.  Secreted ADP activates 
further platelets surrounding the site, making it possible for platelets to activate 
without contact with the vessel wall. (Johnston‐Cox et al., 2011). ADP activates G-
protein coupled receptors P2Y1 and P2Y12  to amplify platelet activation (Storey et al., 
2000). Furthermore, the increase in calcium aids the shape change of platelets into 
activated form of platelets. TxA2 role in platelet activation consists of converting 
arachidonic acid to short lived agent TxA2 through actions by cyclooxygenase-1 
(COX1). TxA2 attaches to its receptor the GPCR thromboxane A2 receptors (TP) and 
further triggers platelet activation (de Groot et al., 2012). In addition to platelet 
activation, the coagulation system is also activated following vascular injury (Triggers 
Mackman, 2008). This produces the platelet activating  factor, thrombin (Sambrano 
et al., 2001). Thrombin generation is driven by the exposure of phosphatidylserine 
(PS) on the platelet and endothelial cell membrane surface enabling further platelet 
activation. (Berndt et al., 2014). At concentrations as low as 0.1 nM , thrombin is able 
to activate platelets (Stalker et al., 2012). Thrombin stimulates two Gq coupled 
receptors, protease-activated receptor (PAR); PAR1 and PAR4 which are expressed on 
human platelets. Together, thrombin generation and these receptors activate 
platelets (Figure 2).  
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2.1.3 Platelet aggregation  
Following platelet activation, integrin αIIbβ3 binds its major ligands, including 
fibrinogen. Integrins are transmembrane receptors involved in cell signalling which 
have cytoplasmic tails of α- and β-subunits.  The integrin αIIbβ3 is usually kept in a 
low affinity conformation “resting” state but after platelet activation transitions to a 
high affinity ligand binding state and this is known as inside-out signalling. For this to 
occur, intracellular activators known as talin and kindlins bind to the β3 integrin tail 
(Shattil et al., 2010).  Additionally, a process known as outside-in signalling occurs 
whereby on extracellular ligand binding to the activated integrin and initiates cell 
signalling events. The extracellular ligand fibrinogen attaches to the αIIbβ3 integrin 
and this mediates platelet aggregation by acting as a bridge to other platelets, thus 
resulting in the aggregation of platelets (Ley et al., 2016).  
Figure 2: Process of platelet activation. Figure adapted from (Periayah et al., 2017). 
Detailed process of platelet activation. Including the activation of protein kinase c 
(PKC) important for secretion of granules and their attachment to their respective 
receptors, increase in calcium for platelet activation.  
 
2.2 Platelet Shape Change 
The platelet cytoskeleton has an important role in maintaining the function of 
platelets in all platelet processes (Fox, 1993). Throughout the platelets function, the 
cytoskeleton rearranges to in each process to regulate platelet function. Resting 
platelets are discoid in shape and the matrix of the interior of platelets is the sol-gel 
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Zone and this is where actin microfilaments, microtubules and intermediary 
filaments- cytoskeletal proteins are stored. The microtubules maintain the 
resting/discoid platelet by forming a closed circular bundle known as marginal band. 
These microtubules of the marginal band are crossed linked and form a bundle 
allowing the platelets to maintain the discoid shape. Additionally, the platelets 
contain cross-linked actin fibres and spectrin that form a lining in the inner surface of 
the plasma membrane (Mathur et al., 2018).  
It is believed that the rearrangement of actin is crucial for platelet shape change 
(Antonipillai et al., 2018), following platelet activation actin polymerisation increases 
and the length of the actin increases too. Actin monomers (G-actin) form filamentous 
actin (F-actin) and during activation, the formation of these F actin increases. These 
filaments form four structures, - filopodia, lamellipodia, stress-like fibres and a 
contractile ring.  
Following platelet activation, the platelet cytoskeleton dismantles and reorganises. 
Platelets change from a spherical discoid shape, by extending pseudopods which 
allows for the platelets to adhere to the surface. This is then followed by an extension 
of the platelet membrane alongside filament arrangement and the formation of 
filopodia and lamellipodia which increases the surface area of the platelets, and is 
known as platelet  spreading. (Sandmann and Köster, 2016).   
2.3 Platelet Agonists  
There are several different platelet agonists that stimulate platelets. The most 
common agonists include ADP, collagen, thrombin, fibrinogen and arachidonic acid. 
2.3.1 Collagen 
Collagen induces platelet activation and has a central role in platelet adhesion and 
initiation of platelet activation. The most important signalling receptor for collagen in 
platelet activation is GPVI. Following interactions between collagen and the receptor, 
platelets trigger strong activation which leads to the release of α- and dense granules 
(Yun et al., 2016). Furthermore, integrin α2β1 is a second receptor for collagen and is 
an important mediator for platelet adhesion (Estevez and Du, 2017). The binding of 
collagen to this integrin triggers outside-in signalling which reinforces platelet 
activation. (Rivera et al., 2009) This makes collagen an important agonist to stimulate 




ADP activates platelets through the P2Y1- Gq coupled receptors and P2Y12- Gi coupled 
receptors which are essential for the platelet activation, aggregation, procoagulant 
activity and thrombus formation under flow. P2Y1 receptor is important for ADP-
mediated platelet shape change and rapidly reversible wave of platelet aggregation. 
P2Y12  has shown to be not as important in causing ADP-mediated shape change as 
the P2Y1 but it does have a role in potentiating TxA2 mediated dense granule secretion 
(Murugappa and Kunapuli, 2006). This makes ADP a potent agonist for platelet 
aggregation to amplify secondary mediator signalling and platelet activation. The 
receptors for the ADP have shown great importance in the development of anti-
platelet drugs such as ADP receptor antagonists like clopidogrel.  Which are used 
frequently in the clinic (Wijeyeratne and Heptinstall, 2011).  
2.3.3 Fibrinogen  
Fibrinogen is a protein involved in platelet aggregation as it binds to integrin αIIbβ3 
and this forms cross-links between platelets allowing them to aggregate and form a 
thrombus. αIIbβ3 is the most abundant cell surface receptors (French and Seligsohn, 
2000). Following the inside-out signalling of the integrin αIIbβ3, outside-in signalling 
of the integrin is initiated by the binding of soluble fibrinogen to the activated integrin 
(Huang et al., 2019) . This facilitates for the cytoskeleton of the platelet to further 
rearrange, spreading of platelets and adhesion. Immobilised fibrinogen affects the 
kinetics of filipodia by extending them and development of lamellipodia in αIIbβ3-
mediated platelet spreading (Jiroušková et al., 2007).  
2.4 Platelet Dysfunction in Cardiovascular disease 
In normal vascular function, platelets circulate around the endothelial wall in the 
vessel without attaching to it (Ruggeri, 1997). However, platelets respond quickly to 
changes in endothelial cells under pathological conditions, including atherosclerotic 
plaque rupture and fatty streak formation. The platelets attach to the site of lesion 
and form thrombi through dysfunctional platelet aggregation and this is associated 
with cardiovascular ischaemic events such as MI and stroke. (Body, 1996). Following 
a plaque rupture, platelets bind to the site of rupture, activate and form a thrombi in 
an intact blood vessel which can result in a MI. Arterial thrombosis is the main cause 
of MI and stroke, these thrombi are rich in platelets and form at sites of high shear 
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stress. Healthy endothelial cells regulate platelet function by limiting platelet 
activation through a release of NO. However, in atherosclerosis, endothelial cells lose 
this ability to limit thrombosis due to decreased secretion of NO (Koupenova et al., 
2017). One of the most common modifications in platelet function in diseased 
conditions is platelet hyperaggregation. This is seen more commonly in patients with 
diabetes mellitus (DM) type 1 and type 2, with DM patients showing an increased risk 
of CVD related events (Ghoshal and Bhattacharyya, 2014).   
2.5 Anti-platelet treatment  
Antiplatelet therapy is vital for the prevention and treatment of an arterial thrombosis 
(Hamilos et al., 2018). Antiplatelet drugs target the activation and aggregation of the 
platelets in order to prevent further thrombus formation. The most commonly used 
anti platelet drugs are aspirin, a cyclooxygenase (COX) inhibitor, and clopidogrel a 
thienopyridine and is a P2Y12 receptor blockers. (Triggers Mackman, 2008).  
Aspirin prevents platelet aggregation by the irreversible inhibition of COX1, which is 
important for the production of TXA2; a vital agonist for the activation of platelets, 
amplification of the platelet response and induces platelet granule release (Behan and 
Storey, 2004).  Aspirin is particularly effective as primary prevention strategy, 
significantly reducing the risk of an MI in men that have a possibility of developing 
CVD (Berger et al., 2006). Furthermore, it is also successful when used as secondary 
prevention, reducing the risk of a second MI in patients (Hennekens et al., 2006). 
However, despite these benefits, aspirin is associated with  excessive bleeding events, 
with long-term aspirin therapy linked to a substantial increase in the occurrence of 
gastrointestinal haemorrhage (Gregg and Goldschmidt-Clermont, 2003).  
The thienopyridine class of antiplatelet drugs work by blocking ADP from binding to 
one of its receptors; P2Y12, reducing platelet activation (Gachet and Hechler, 2005). 
The most commonly used drug in this class is clopidogrel, which is used for the 
treatment of Acute Coronary Syndrome (ACS) (Cannon et al., 2007). Other 
thienopyridines such as ticlopidine, have had limited use due to the side effects 
associated with treatment the most serious being neutropenia accounting for 2.1% of  
ticlopidine-treated patients which sometimes results in fatalities (Quinn and 
Fitzgerald, 1999) (Valgimigli et al., 2018). Another recently developed P2Y12 antagonist 
prasugrel is similar to clopidogrel in that it involves hepatic metabolism to make an 
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active metabolite, which performs as an irreversibly binding P2Y12 antagonist (Hamilos 
et al., 2018). A study showed that prasugrel had decreased the amount of ischaemic 
events but increased the risk of bleeding compared to clopidogrel suggesting that 
prasugrel is more potent (Triggers Mackman, 2008).  
A combination of anti-platelet therapies has been recognised as being significantly 
better at reducing and treating cardiovascular ischaemic events compared to single 
drug use. As aspirin and clopidogrel work by inhibiting different platelet activation 
pathways, dual antiplatelet therapy is now used. In clinical trials, patients with ACS 
without ST-segment elevation received clopidogrel in addition to aspirin as opposed 
to another group who received a placebo drug in addition to the aspirin. Results found 
a benefit of taking clopidogrel in the first 30 days, which continued during the 12 
months of the trial. However, an increase in severe bleeding events in the group with 
clopidogrel compared to the placebo group (aspirin alone) was observed (Yusuf, 
2001). Moreover, a randomised trials suggests that taking both aspirin and clopidogrel 
together or any P2Y12 inhibitor together with aspirin offers no increased protection 
and in fact decreases efficacy of the P2Y12 compared to group who took a lower dose 
of Aspirin that had a reduction in cardiovascular event (Warner et al., 2011).  This 
highlights the disadvantages and risks of current anti platelet therapy and this gives 
rise to the need to identify novel compounds to develop as an anti-platelet therapy.  
2.6 Diet and CVD 
There is substantial evidence that associates healthy diets and a decrease in 
cardiovascular risk and an improvement of cardiovascular health (Casas et al., 2018). 
Unhealthy dietary patterns are associated with an increased risk of CVD such as intake 
of processed foods, increased sodium, unhealthy fats and a decreased intake of fruit 
and vegetables, fish, grains and nuts (Anand et al., 2015). For this reason, research 
into how a healthy diet can improve cardiovascular health is a priority. For instance, 
research has shown that a Western diet, generally a meat -based diet has shown 
higher levels of proinflammatory markers and decreased anti-inflammatory markers 
whilst “healthy” diets like the Mediterranean diet have shown the opposite with anti-
inflammatory and cardioprotective effects. (Barbaresko et al., 2013). Furthermore, 
the Mediterranean diet has shown to decrease and modulate pro-atherothrombotic 
genes such as cyclooxygenase-2 (COX-2) and monocyte chemoattractant protein 
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(MCP-1) important for leukocyte recruitment (Esposito et al., 2006).  This is central for 
research into atherosclerosis as a decrease in these genes reduces plaque stability. In 
atherosclerosis, platelets adhere to the endothelial cells contributing to recruitment 
of leukocytes thus contributing to inflammation (Nishijima et al., 2004).  
In addition to their role in the formation of a thrombus, following a plaque rupture 
resulting in life threatening ischaemic events, platelets also have a role in intensifying 
inflammation through use of pro-atherogenic actions at all stages of atherosclerosis. 
They do this by helping the interaction between immune and endothelial cells by 
expressing molecules such as p-selectin (cell surface adhesion molecule found in α 
granules within platelets) (Fuentes Q et al., 2013). With the evidence of a positive link 
between healthy diet and atherosclerosis and platelets role in CVD, research into diet 
and dietary compounds as an anti-platelet agent is important as a primary prevention.  
2.7 Anti-platelet properties of Dietary compounds 
Research into natural dietary compounds have identified several dietary derived 
compounds with anti-platelet properties, which supports the link that a healthy diet 
decreases CVD.  
2.7.1 Adenosine 
A research study isolated and studied the antiplatelet effects of bioactive compound 
of ripe tomato (Solanum lycopersicum). Reversed-phase high-performance liquid 
chromatography (HPLC) was used to establish the concentration of adenosine in the 
tomato fruit (pulp and skin extracts) and the by-products (paste and pomace). 
Adenosine is an endogenous anti-aggregating substance which influences the activity 
of platelets by increasing the levels of 3′,5′-cyclic adenosine monophosphate (cAMP) 
and 3′,5′-cyclic guanosine monophosphate (cGMP) which inhibit platelet activity 
(Anfossi et al., 2002). A higher concentration of adenosine was found in aqueous 
extracts which resulted in inhibition towards platelet aggregation, adhesion and 
secretion as well as platelet thrombus formation (Fuentes et al., 2012). 
2.7.2 Polyphenols 
Inhibition of platelet function was observed following treatment with dietary 
polyphenols. Polyphenols are naturally occurring bioactive compounds that are 
characterised by their structure, this includes the amount of phenol rings they 
contain. Due to the difference in structure, the polyphenols are classified into 
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different groups and can vary in size depending on the phenolic structure (Ludovici et 
al., 2018).  They act as secondary metabolites for plants and are generally found in 
vegetables, fruits, drinks and cereals (Beckman, 2000). 
Several studies have shown that polyphenols elicit inhibition towards platelet 
function. One study used olive leaf extracts which are rich in the polyphenol 
oleuropein. The study found that oleuropein inhibited platelet aggregation in whole 
blood in a dose dependant manner. The study suggested that this was possibly due to 
their reactive oxygen species (ROS) - hydrogen peroxide (H2O2) scavenging properties 
and although the data shows that there is an inhibition of platelet function, the 
mechanism by which they elicit this activity has not yet been discovered (Singh et al., 
2008). Furthermore, previous literature has found that oleuropein is not the only 
polyphenol found in olive leaves and another study (Talhaoui et al.) found various 
other polyphenols in olive leaf but that there was a larger concentration of 
oleuropein. Other polyphenols isolated included hydroxytyrosol, caffeic acid, luteolin, 
rutin and catechin. These polyphenols are also recognised to have antioxidant and 
H2O2 scavenging properties. The study suggested that the polyphenols are working 
together to inhibit platelet function as the polyphenols have the ability to show 
synergistic behaviour, however further work is required to quantify the polyphenols 
in olive leaf extract and determine the mechanism by which they inhibit platelet 
function.  
In addition, another study investigating chlorogenic acid a polyphenol found 
abundantly in different foods including apples, kiwis, eggplants and coffee. The study 
found that chlorogenic acid  inhibited ADP induced P-selectin expression and 
GPIIb/IIIa activation (Fuentes et al., 2014). P-selectin is also an inflammatory 
mediator. Chlorogenic acid was also shown to reduce ADP and collagen induced 
platelet aggregation. The study observed attenuation of platelet adhesion and 
aggregation formation on collagen under flow conditions following treatment of 
whole blood with chlorogenic acid. The study wanted to see whether the inhibition of 
platelet aggregation was due to an increase in cAMP levels (secondary messenger 
which inhibits platelet function modulating platelet function when activated), cAMP 
levels had increased with chlorogenic acid present and they had associated the 
inhibition of platelet aggregation with this increase.  Moreover, Protein Kinase A (PKA) 
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– a potent antagonist of platelet activation (cAMP dependent) that maintains 
circulating platelets in a resting state was found to be increased with chlorogenic acid 
(Fuentes et al., 2014). 
2.7.3 Flavonoids 
Various studies have identified that flavonoids; a class of polyphenols that are found 
widely in fruits and vegetables and their secondary metabolites also have inhibitory 
effects on platelet function.  
Hesperetin is a flavonoid found in grapefruits and oranges which showed inhibition of 
agonist induced platelet aggregation following stimulation by collagen and 
arachidonic acid through the inhibition of PLCγ2 phosphorylation and COX1 (Jin et al., 
2007). The study demonstrated that hesperetin inhibited arachidonic acid mediated 
platelet aggregation, preventing production of TxA2 and prostaglandin D2 (PGD2) 
both produced by the COX1 pathway in platelets thus inhibiting platelet aggregation. 
In addition, hesperetin inhibited collagen mediated platelet aggregation. As collagen 
induces platelet activation through PLCγ2 resulting in increased calcium, which 
regulates platelet shape change and granule release, hesperetin was found to inhibit 
cytosolic calcium mobilisation and platelet function.  
Another flavonoid that shows strong anti-platelet properties is tangeretin, a 
polymethoxylated flavone found abundantly in the peel of citrus fruits. The study 
found that tangeretin inhibited collagen-induced platelet aggregation in a 
concentration dependant manner. However, thrombin-induced platelet aggregation 
was inhibited at a lower concentration than collagen. Platelet aggregation is 
modulated by the integrin αIIbβ3 by inside-out signalling to increase fibrinogens 
ability to bind the integrin, treatment with tangeretin was found to inhibit the integrin 
αIIbβ3 inside-out signalling determined by measuring the fibrinogen binding. 
Moreover, tangeretin inhibited α-granule secretion, measured by P-selectin 
exposure. In addition to this, tangeretin also inhibited calcium mobilisation and 
tangeretin treatment resulted in reduced thrombus formation. These inhibitory 
effects were found to be due to an increase in the levels of cGMP, a key inhibitory 
mediator of platelet inhibition. This study went further, identifying that tangeritin 
showed no alteration of phosphodiesterase activity, indicating tangeritin does not 
increase cGMP by increasing hydrolysis of cGMP. The authors conclude that this 
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indicates that tangeretin increases the production of cGMP via regulation of guanylyl 
cyclase activity. (Vaiyapuri et al., 2013).   
Structurally similar to tangeretin, nobiletin is a flavonoid found abundant in the peel 
of citrus fruits. The study reported that nobiletin inhibited platelet activation 
following stimulation with collagen and collagen-related peptide (CRP-XL) which is a 
GPVI specific agonist. Nobiletin was also able to inhibit aggregation through the 
inhibition of the integrin αIIbβ3. Similar to tangeretin, nobiletin inhibited platelet 
granule secretion and calcium mobilisation. Additionally, treatment with nobiletin 
affected the outside-in signalling of integrin αIIbβ3 by inhibiting clot formation with 
nobiletin. Of all the concentrations of nobiletin used, there was a clear reduction of 
thrombus formation compared to the vehicle. Nobiliten also increased cGMP levels 
like tangeretin and is not dependant on stimulation by agonist or platelet activation. 
The study further investigated and found that vasodilator-stimulated phosphoprotein 
(VASP) phosphorylation was also increased, which is phosphorylated by PKG – cGMP 
dependant protein kinase, indicating as with tangeritin, nobiletin regulates guanylyl 
cyclase activity (Vaiyapuri et al., 2015).  
2.8 Cucurbitacins 
Cucurbitacins are a large family of triterpenoid compounds found in a plant family 
known as cucurbitacea (figure 3). Cucurbitacins are characterised by tetracyclic 
cucurbitane nucleus skeleton called 19-(10→9-β)-abeo-5 alpha- lanostane (also 
known as 9-β-methyl-19-nor-lanosta-5-ene) (Alghasham, 2013). Chemically, 
cucurbitacins have different characteristics and are subdivided into 12 groups, most 
found in curcurbit group  (Figure 3) (Chen et al., 2005). Originally, cucurbitacins were 
isolated from cucurbitacae but were later found in other plants of families including 
Scrophulariaceae, rassicaceae, Thymelaeaceae, Datiscaceae, Begoniaceae, 
Elaeocarpaceae, Polemoniaceae, Desfontainiaceae, Primulaceae, Rubiaceae, 
Sterculiaceae, Rosaceae (Chen et al., 2005). Cucurbitacins are found in edible 
vegetables and fruits, for instance cucumbers, squash, melons and watermelons but 
in low concentrations (Gry, 2006). Traditionally, used as folk remedies they have been 
shown to possess a wide range of pharmacological activities. Including their cytotoxic 
properties which gives some vegetables a bitter taste to deter animals in consuming 
the plant in excess. (Kaushik et al., 2015).  
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Several cucurbitacins have been shown to have several anticancer and anti-
inflammatory activities. Cucurbitacins elicit cytotoxic activity on breast cancer cell 
lines such as SKBR-3 and MCF-7. (Dakeng et al., 2012). In vitro proliferation activity of 
cucurbitacin B was found to significantly inhibit the growth of colon (HCT-116), breast 
(MCF-7), lung (NCI-H460) and central nervous system (SF-268) cancer cell lines. 











Figure 3: Structure of cucurbitacins. A) The structure of cucurbitacin A, B and D. B) 
Structure of E, I, J and K  
 
Cucurbitacin D has also shown cytotoxicity towards many human cancer cell lines, 
such as lung cancer, brain cancer, breast and some human colon cancer cell lines 
(Jayaprakasam et al., 2003).  Cucurbitacin E inhibits cell adhesion by disrupting the 
cytoskeleton of JY and HeLa cell lines (Musza et al., 1994) and has shown antitumor 
activity on ovarian sarcomas and prostate carcinomas (K. L. Duncan et al., 1996). 
Similarly, cucurbitacin I displays cytotoxicity towards KB human cell cultures (Chen et 
al., 2005) and anti-tumour activities in other cancers such as colon, breast, lung and 
brain. In addition to their cytotoxic anti-cancer properties, Cucurbitacins B, D, E and I 
have been reported to show inhibition of COX-2 enzymes, important for promoting 
inflammation but not COX-1 (responsible for thromboxane A2 synthesis) 
(Jayaprakasam et al., 2003). Reports have shown cucurbitacin B and E to elicit 
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inhibitory effects on products of lipid oxidation as lipid oxidation causes damage to 
cells through the degradation of lipids on the lipid membrane by free radicals. (Tannin-
Spitz et al., 2007).  This highlights the cucurbitacins potential as a preventative 
treatment for atherosclerosis as lipid oxidation plays a role in plaque formation. Taken 
together these reports identify cucurbitacins as future potential anti-atherosclerotic, 
anti-cancer and anti-inflammatory therapies. However, the antiplatelet activity of 
cucurbitacins is unknown. Therefore, this study will investigate the anti-platelet 
activity of cucurbitacins by monitoring the effect of cucurbitacin treatment on platelet 
function including measurement of platelet aggregation, platelet adhesion and 
thrombus formation. 
2.9 Aims 
The aim of this study is to identify the effect of the dietary compounds cucurbitacins 
on platelet function and thrombus formation.  
2.10 Objectives 
This project sets out to establish the effect of cucurbitacin compounds on the 
underlying cellular events of platelet function and thrombosis. We will do this by 
achieving the following objectives: 
1. Investigate the anti-platelet properties of cucurbitacins ex vivo. 
2. Investigate the anti-thrombotic properties of cucurbitacins using in vitro ex 
vivo assays. 
3. Investigate the role for cucurbitacins in the regulation of platelet signalling 
components. 
2.11 Hypothesis 
We hypothesise that cucurbitacins B, E and I will have an effect on platelet function 
and elicit anti-platelet properties. 
2.11.1 Null Hypothesis 
We hypothesise that cucurbitacin B, E and I will show no anti-platelet properties and 





3 Materials and Methods 
3.1 Blood collection 
Informed consent was obtained, and blood taken from healthy, aspirin-free human 
volunteers into 4% sodium citrate according to ethical standards approved by 
Manchester Metropolitan University Ethics committee, ETHOS: 14849 (Appendix 1) 
3.2 Platelet preparation  
3.2.1 Platelet rich plasma  
For platelet rich plasma (PRP), citrated whole blood was centrifuged at 100 xg for 20 
minutes at room temperature and the supernatant PRP collected into falcon tubes.  
3.2.2 Washed platelets 
For washed platelet preparation, following protocol to prepare PRP. Add 150µLof Acid 
citrate dextrose ACD (29.9 mM trisodium citrate, 113.8 mM glucose and 2.9 mM citric 
acid [pH 6.4]) per ml of PRP and then centrifuge at 350 xg for 20 minutes. Remove the 
supernatant and re-suspend the platelet pellet in Tyrodes- HEPES buffer (134mM 
NaCl, 2.9mM KCl, 0.34mM Na2HPO4.12H2O, 12mM NaHCO3, 20mM HEPES and 1mM 
MgCl2 [pH 7.3]) containing glucose. Platelets were counted using Sysmex Blood 
analyser to guarantee at least a concentration of 2x108 cells/ml.  
3.3 Aggregation Assay 
3.3.1 End-point – 96 well plate-based aggregation assay 
Platelet aggregation was determined using optical aggregometry. For the end-point 
96 well plate-based aggregation assay, agonists were prepared at 10 x final 
concentration in Tyrodes buffer as shown in table 6. A stock concentration of 10μg/ml 
of collagen (LabMedics - 300-0385) (-0.03-30µg/mL) and ADP (Sigma Aldrich – A5285) 
(0.01-10 µM) solution was used to make a collagen and ADP serial dilution series. The 
cucurbitacins (Cambridge Biosciences, Cucurbitacin B - CAY14820-1 mg, Cucurbitacin 
E - CAY14821-1 mg , Cucurbitacin I - CAY14747-1 mg) were also prepared at 10x final 
volume (0. 0.1, 0.3, 1, 3, 10 µM). A 10% Dimethyl sulfoxide (DMSO) (Sigma-Aldrich 
10213810) -tyrodes mix was prepared for the cucurbitacin serial dilution (final 
concentration of DMSO 0.1%). Using a multichannel pipette, 4.5μL of cucurbitacins 
was added to half area, flat-bottom, clear 96-well microtiter plate. The PRP or washed 
platelets were transferred to a reservoir and using a multichannel pipette 40.5 μL of 
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platelets were transferred into each cucurbitacin/vehicle containing well of the half 
area plate using inverse pipetting to avoid creating bubbles. This was incubated at 
room temperature for 10 minutes. A plate shaker was pre heated to 37oC, and 
following 10 minutes of cucurbitacin incubation, platelet activation was stimulated by 
adding 5μL of agonist (collagen or ADP) into the corresponding the wells, and the 96 
well plate was then shaken for 5 minutes at 1,200 rpm at 37oC. Light absorbance was 
measured at 450 nm using a Synergy HT microplate reader. Light absorbance is a 
measure of platelet aggregation as is based on principle that light passes easier 
through a clear solution than when turbid. When platelet aggregates form, less light 
is absorbed, resulting in reduced absorbance and increased light transmission which 
is proportional to the amount of aggregation.  
Table 1: Table showing dilutions of ADP, Collagen and Cucurbitacins in 96-well full 
area plate.  
 ADP (µM) Collagen (µg/mL) Cucurbitacin (µM) 
A 10  10  10  
B 3 3 3 
C 1 1 1 
D 0.3 0. 0.3 
E 0. 0.1 0.1 
F 0.03 0.03 0 (Vehicle) 
G 0.01 0.01 ////////////// 
H 0 (Vehicle) 0 (Vehicle) /////////////// 
 
3.3.2 Analysis of platelet aggregation 
Light absorbance is converted to %light transmission (%LT) using the equation: 
 %LT = 10-ABS x 100  
To convert %LT to % Aggregation, the following equation is used: 
 %Aggregation = 100/ (Resting – Blank) x %LT – Blank.  
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A dose response curve for each agonist and cucurbitacin was then plotted using 
GraphPad prism using a dose-response –stimulation curve analysis.  
3.3.3 Real Time Aggregation 
Real time aggregation is the “gold standard” turbidimetric platelet aggregation assay 
which uses optical aggregometry and measures light transmission over time using an 
aggregometer. A stock concentration of 100µM of ADP and collagen (100 µg/mL) was 
prepared in tyrodes buffer. Different concentrations of cucurbitacin were prepared at 
a 100x final concentration (final concentrations; 10, 1, 0.1 µm) that were used and 
10% DMSO containing tyrodes buffer used as a diluent and vehicle control. In separate 
cuvettes, 2.5 µl (1/100 volume) of the different concentrations of cucurbitacins and 
vehicle was incubated with 225 µl of washed platelets. The cuvettes were placed into 
CHRONO-LOG® Model 700 Whole Blood/Optical Lumi-Aggregometers and baseline 
set in comparison to 250 µL of tyrodes buffer solution. The solution was stirred at 
1200 rpm at 37 oC. After one minute, to establish baseline, the platelets were 
stimulated with 25 µL (1/10th volume) of the agonists ADP (10 µM final) and collagen 
(1 µg/mL final). Aggregation was measured for 5 minutes. 
  
3.4 Platelet Adhesion and Spreading 
Wells of a full area flat-bottomed 96-well plate were coated with 50 µL of fibrinogen 
(Sigma-Aldrich - F3879-100MG) (100 µg/ml) or 1% Bovine serum albumin (BSA) 
(Sigma-Aldrich  -  A7030-10G) (5 µg/mL) either overnight at 4 oC or for 1 hour for 37 
oC. The wells were then washed with tyrodes buffer and then blocked with 50 µL of 
1% BSA (5 µg/mL) and left for 1 hour at room temperature. After blocking the BSA is 
washed off three times with tyrodes buffer. Cucurbitacins were prepared at 10x final 
concentration (final concentrations; 0. 0.1, 0.3, 1, 3, 10 µM). A 10% DMSO-tyrodes 
mix was used as a diluent (final concentration 0.1% DMSO). 5µL (1/10th volume) of 
each cucurbitacin concentration was added to 45 µL of washed platelets at 2x107 
cell/mL and allowed to incubate for 10 minutes. 50 µL of cucurbitacin or vehicle 
control treated platelets was added to the fibrinogen and BSA coated wells and left 
to adhere at room temperature for 1 hour. Unbound platelets were aspirated off and 
discarded and wells washed with tyrodes buffer. Care was taken to not dislodge any 
adhered platelets. Adhered platelets were then fixed with addition of 50 µL of 4% 
Paraformaldehyde (PFA) (Sigma-Aldrich P6148) for 10 minutes, then washed again 
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with PBS (137 mM NaCl, 10 mM Na2HPO4, 2.7 Mm KCl, 2 mM KH2PO4 [pH 7.4]). To 
enable visualisation, adhered platelet was stained with 3,3′-Dihexyloxacarbocyanine 
iodide (DiOC6) (Sigma-Aldrich 318426-250mg) or Alexa-rhodamine conjugated 
phalloidin (Life Technologies- ThermoFisher Scientific A12379). 50 µL of DiOC6 (10 
µM)/phalloidin in tyrodes buffer was added to the wells and incubated for 1 hour then 
removed and wells washed with tyrodes. The plate was stored in the dark at 4oC until 
imaging.  
3.4.1 Imaging and analysis 
Fluorescent images of the adherent platelets were captured using CELENA S Digital 
Imaging system with the 20x objective lens. One image was captured at the centre of 
each of the well and analysed, atleast 100 platelets in the control sample was counted. 
Only one well per concentration was captured and analysed. Image J software was 
used to quantify the number of platelets that adhered to the plate (DiOC6) and total 
surface area covered by platelets that adhered and the average size of each platelet 
(phalloidin). The average platelet area was estimated  by dividing the total surface 
area coverage by the number of platelets adhered on fibrinogen once corrected for 
non-specific BSA binding. To correct for non-specific binding, number of BSA adhered 
platelets were subtracted from the fibrinogen adhered platelets. Whilst attempts 
were made to set the ImageJ threshold (see following section) so that overlapping 
platelets were counted individually, manual checks revealed this was not always the 
case, therefore average platelet size can only be considered an ‘estimate’.   
When imaging the wells, one image was taken in both pseudocolor for presentation 
of representative images and monochrome as seen in figure 4 and figure 5 For image 
J analysis, the monochrome image was used, and a ‘threshold’ was created to identify 












Figure 4: Imaging and Analysis of DIOC6 staining of Cucurbitacin B. One fibrinogen 
image captured at 20x objective per well and analysed. A) 0 µL of cucurbitacin B. B) 10 
µL of Cucurbitacin B. I) pseudo colour image, II) monochrome image and III) Threshold 




Figure 5: Imagine and Analysis of Phalloidin Staining of Cucurbitacin B. One 
fibrinogen image captured at 20x objective per well and analysed A) 0 µL of 
cucurbitacin B. B) 10 µL of Cucurbitacin B. I) pseudo colour image, II) monochrome 
image and III) Threshold image created in image J for analysis.    
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3.4.2 Platelet adhesion and spreading analysis in Image J 
 
For platelet adhesion and spreading data analysis, images were opened in image J and 
a ‘threshold’ was created and background adjusted to detect adhered platelets 
(Figure 6-E). Number of platelets per image was quantified by  using the ‘analysis’ and 
‘outlines’ option within Image j which can be adjusted for size or circularity. The data 
is expressed as the total number of platelets, the total area of the platelets and 
average size of the platelets (Figure 6H). A step by step guide of the image J analysis 










































Figure 6: Image J analysis of platelet adhesion and spreading. Step by step guide to 
analyse an image to count how many particles (platelets) and the average surface 
area of each particle in image J. A) Task bar for image J with all the options required 
to analyse. B) Threshold extension tab. C) The image created once a threshold is 
created. D) The intensity of fluorescence that shows in the image that shows each 
single platelet clear. E) The image created with the threshold. F) Image it is converted 
to be able to be analysed. G) Analysis extension tab to analyse the image with options 
of changing size of particles to be recognised and analysed. H) Summary of results, 























3.5 Thrombus formation under flow  
10µM DiOC6 (stains the platelet membrane) labelled human whole blood was treated 
with 10 µM of Cucurbitacin B, E or I or vehicle (0.1% DMSO) for 10 minutes. Channels 
of Vena8Fluor+ Biochips (Cellix), were coated overnight at 4o with collagen (100 
µg/mL), then blocked with 1% BSA for one hour at room temperature and washed and 
replaced with PBS. Cucurbitacin pre-treated whole blood was perfused over the 
collagen coated Vena8fluor chips at an arterial shear rate 20 dyn/cm2 (1000s-1) for 10 
minutes. A 20-x magnification lens on a Nikon A1-R confocal microscope was used to 
visualise platelet adherence and thrombus formation. Image J was used to analyse 
and determine surface area coverage, fluorescence intensity and the thrombus 
instability index (Δ Sd/ Δ T (%)) – change in surface distribution relative to change in 
time (Pugh et al., 2017), This is a measurement of objects in the video that haven’t 
adhered and move from frame to frame , indicating instability these are determined 
as follows:  
3.5.1 Δ Sd/ Δ T (%) analysis in Image J  
 
Nikon ND2 plugin for image J was used to open the ND2 video file (Figure 7A), and the 
converted into an image sequence (Figure 7B). Frames at 10 second intervals were 
analysed (Figure 7C) to enable the distinction of movement (instability index) of the 
platelets. Like the previous image J platelet adhesion analysis, a threshold was created 
to recognise the platelets movement per image. The images were analysed for % 
surface area coverage of the thrombus. Furthermore, the images were analyses to 
find Δ Sd/ Δ T (%) which is a record of the change in surface distribution with time. 
The images were duplicated and one slice from the start of one duplicate was deleted 
and the end image of the second duplicate (Figure 7 E). Once deleted, the image 
sequence was subtracted from one another (Figure 7 F). This visualised the 
thrombi/platelets that appear to be moving/unstable and anything stable was 
eliminated. This was further analysed, and the data was presented as Δ Sd/ Δ T (%) 
which is the δ in surface distribution relative to change in time. A step by step guide 
























Figure 7: Image J analysis of thrombus formation video. Step-by-step guide on how 
to analyse the thrombus formation videos to attain the % surface area coverage of 
each frame and Δ Sd/ Δ T (%)– a record of the change in surface distribution with time. 
A) ND2 plugin file for the video. B) The ND2 video opened in image J and option to 
convert to a video sequence. C) Video sequence with a frame every 8th image. D) 8 bit 
video with a threshold created for analysis. E) Second part of the analysis process with 
option to duplicate the video and delete a slice from the beginning of one video and 
end of the other video. F) The image calculator option to subtract both videos. G) The 
end of non-subtracted video to analyse surface area of coverage. H) The end of 
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3.6 Flow Cytometry  
3.6.1 Fibrinogen Binding – integrin GPIIb/IIIa activation 
Platelet rich plasma was diluted 1/10 in tyrodes buffer and treated with increasing 
concentrations of cucurbitacins (0.1, 1, 10 µM) or vehicle control (0.1% 
DMSO/Tyrode’s). An unstimulated (resting) sample and unstained sample were also 
prepared as negative controls and for gating. Cucurbitacin treated samples were 
stimulated with ADP (10 µM) and left to incubate with an anti-fibrinogen (Polyclonal 
Rabbit Anti-Human Fibrinogen/FITC Agilent Dako F0111) antibody for 30 minutes in 
the dark at room temperature. The samples were then fixed with 2% 
paraformaldehyde for 10 minutes. Data for 10,000 events in the platelet gate were 
collected for each sample using a MACSQuant (Miltenyi Biotec MACSQuant 16) flow 
cytometer and analysed using FlowJo software to determine median fluorescence 
intensity. Samples were prepared as follows (table 7):  
Table 2: Table showing the samples prepared for Fibrinogen binding  
Sample Agonist PRP + antibody mix 2% PFA  
Cucurbitacin B – 10 µM ADP Antibody PFA 
Cucurbitacin B – 1 µM ADP Antibody PFA 
Cucurbitacin B – 0.1 µM ADP Antibody PFA 
Vehicle ADP Antibody PFA 
Cucurbitacin E – 10 µM ADP Antibody PFA 
Cucurbitacin E – 1 µM ADP Antibody PFA 
Cucurbitacin E – 0.1 µM ADP Antibody PFA 
Vehicle ADP Antibody PFA 
Cucurbitacin I – 10 µM ADP Antibody PFA 
Cucurbitacin I – 1 µM ADP Antibody PFA 
Cucurbitacin I – 0.1 µM ADP Antibody PFA 
Vehicle ADP Antibody PFA 
Unstimulated - Antibody PFA 




3.6.2 Actin Polymerisation 
Human washed platelets prepared at 8x108/mL in tyrodes HEPEs buffer were treated 
with increasing concentrations of cucurbitacins (0.1, 1, 10 µM) and 0.1% 
DMSO/tyrodes as vehicle control which was left to incubate for 10 minutes. ADP (10 
µM) stimulated platelets with no cucurbitacin was added as positive control and ADP 
was only added to this one sample and not in the cucurbitacin treated platelets. An 
unstained sample (negative control) was also prepared with platelets and tyrodes to 
enable gating on flow cytometer. All samples were fixed with 2% paraformaldehyde 
and centrifuged for 10 minutes at 1000 xg at 4°C. The supernatants are discarded and 
resuspended in tyrodes buffer then centrifuged again with the same centrifuge 
settings as stated above. The pellet was then resuspended with BD Phosflow Perm 
Buffer III (BD Biosciences) and incubated on ice for 30 minutes. Once incubation is 
over, the samples are centrifuged again and resuspended in Tyrode’s to wash and 
centrifuged once more. The samples except for the unstained samples were stained 
with Tyrode’s containing conjugated phalloidin (Alexa-488) to detect F-actin for 30 
minutes in the dark. Data for 10,000 events per sample were collected in the platelet 
gate using a MACSQuant (Miltenyi Biotec MACSQuant 16) flow cytometer and 
analysed using FlowJo software to determine median fluorescence intensity. 
3.7 Western Blotting 
3.7.1 Preparation of platelet lysates. 
Human washed platelets were resuspended to 4 x 108 /ml in modified Tyrodes HEPEs 
buffer and increasing concentrations of cucurbitacin B, E and I prepared at a 10x final 
concentration (final concentrations; 10, 1, 0.1 µM) and 10% DMSO containing tyrodes 
buffer used as a diluent and vehicle control (final concentration 0.1%). Platelets were 
incubated with the increasing concentrations of cucurbitacins or vehicle control 10 
minutes at room temperature. Platelets were also stimulated with ADP (10µM) for 10 
minutes as a positive control. Following incubation, lysates were prepared by addition 
of an equal volume of laemlli buffer (1M Tris-HCl , 8% Sodium Dodecyl Sulfate (SDS), 
40% glycerol, β-mercaptoethanol, 0.5 M Ethylenediaminetetraacetic acid (EDTA), 
bromophenol Blue [pH 6.8]) and heated to 90oC for 5 minutes, before storage at -20C 
for future use. 
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3.7.2 SDS-PAGE and Blotting 
Samples were separated by SDS PAGE using pre-cast gradient 4-20% Tris-Bis gels and 
15µL samples loaded as per table 8.  The SDS PAGE gel was run with Tris-glycine 
Running biffer (192 mM Glycine, 25 Mm Tris, 1% SDS [pH 8.3]) at 90 volts for 10 
minutes then 130 volts at 50 minutes until bands have reached black line of gel.  
Separated samples were then transferred onto Polyvinylidene difluoride (PVDF) 
membrane with 1% Transfer buffer (Tris Glycine 10x transfer buffer- 192 mM Glycine, 
25 Mm Tris, 20% Methanol) at 90v for 90 minutes at 4°C. Following transfer, the PDVF 
membrane was blocked with 5% BSA (50ml TBST and 2.5 mg BSA) for 1 hour at room 
temperature.  
Table 3: Order of lysates gel. Veh = vehicle control (0.1% DMSO) 
Well 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Ladder X              
Cucurbitacin  B B B  E E E  I I I   
Control     Veh    Veh    Veh ADP 
µM  10 1 0.1 0 10 1 0.1 0 10 1 0.1 0 10 
 
Primary antibodies were prepared in BSA (5%) anti-Actin (AC-15 Anti-beta Actin - 
ab6276, ABCAM) antibody was prepared at 1:5000, (2 µL of actin and 10ml of BSA), 
and anti-phospho-myosin light chain 2 (Ser19) ( pS19 Myosin Light chain 2 – 3671, Cell 
signalling technologies) was prepared at 1:1000 (5 µL in 5ml of BSA) and incubated at 
4oC overnight. Blots were then washed 3 times for 10 minutes with Tris buffered saline 
Tween-20 (TBS-T) (10Mm Tris, 150 mM NaCl, 0.2% Tween- 20) with agitation. 
Secondary antibodies were prepared. Goat anti-Rabbit IgG Secondary Antibody (Li-
cor - 926-32211) and Goat anti-Mouse IgG Secondary Antibody (Li-cor - 926-32210) at 
1;10000 (1 µL of antibody in 10ml of BSA) and membranes incubated in light sensitive 
containers on a rocker for 1 hour at room temperature. The membranes were washed 
again 3 times for 10 minutes with TBST. Membranes were imaged using the Li-cor 
Odyssey Fc, for fluorescence intensity. ImageJ was used to quantify band density and 
fluorescence intensity.  
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3.8 Statistics  
All experiments were performed at least in triplicate. The data obtained from plate-
based aggregation, real time aggregation and in vitro thrombus formation, DIOC6 
stained adhesion 96-well were analysed using two-way Anova. Phalloidin stained 
adhesion 96-well plate were analysed using one-way Anova. Median fluorescence 
intensity value as obtained in fibrinogen binding and actin polymerisation assays were 
analysed using Kruskall-wallis (parametric and non-parametric) test. All tests were 
performed on GraphPad Prism (version 8.01) from graphpad Software Inc. P≤0.05 was 
considered statistically significant. Values were all expressed as mean ±SEM.  
4 Results 
4.1 Cucurbitacins inhibits platelet aggregation.  
Previous studies have shown that cucurbitacins can disrupt integrin signalling in 
breast cancer cell lines, specifically ITGA6 and ITGB4 (integrin α6 & integrin β4) which 
are overexpressed in breast cancer (Gupta and Srivastava, 2014). Integrin αIIbβ3 
mediates platelet aggregation and is the dominant integrin in platelet function and 
essential for platelet aggregation. Therefore end-point aggregometry was used to 
analyse the effects of increasing concentrations of cucurbitacins B, E and I on integrin 
function and platelet aggregation. Both human platelet rich plasma (figure 8 and 
figure 10) and washed platelets (figure 9 and figure 11), were treated with increasing 
concentrations of cucurbitacin B, E or I (0, 0.1, 0.3, 1, 3, 10 µM), and aggregation to 
collagen (0.03-30 µg/mL) (Figure 8 and Figure 9) and ADP (0.01-10 µM) (Figure 10 and 
Figure 11) was determined after 5 minutes by monitoring light transmission. 
Treatment with either of the different cucurbitacin derivatives caused a dose 
dependent attenuation in platelet aggregation following stimulation with agonists 
collagen (Figures 8 and 9) and ADP (Figures 10 and 11). Following treatment of 
platelets with the highest concentration of all cucurbitacins (10 µM), aggregation was 
compared across increasing agonist concentrations, and a reduction in the amount of 
aggregation was observed. Despite an overall inhibition of aggregation, treatment 
with the cucurbitacins did not seem to affect the sensitivity of the aggregation to 
collagen or ADP, as the EC50 for either agonist was unchanged following treatment 
with 10uM Cucurbitacin B, E or I (Figure 8, 9, 10 and 11 A). The inhibition caused by 
cucurbitacins was not overcome by the increasing concentrations of collagen and 
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ADP. The IC50 for all cucurbitacins are all similar at all concentrations of ADP and 
collagen tested (Figure 8B, 9B, 10B and 11 B). Although inhibition is observed in both 
PRP and WP, it is elevated in WP (figure 9 and figure 11) compared to PRP (figure 8 
and figure 10). For example, whilst aggregation to ADP was not significantly altered 
following treatment with 10µM cucurbitacin I in PRP compared to the vehicle (Figure 
10A II), a significant inhibition of aggregation was observed compared to the vehicle 
in washed platelets (Figure 11A II). Similar results were observed with cucurbitacin B 
and E. This is likely due to cucurbitacin binding to plasma proteins in PRP, therefore 
decreasing their ability to inhibit aggregation. In conclusion we observed, cucurbitacin 
mediated inhibition of platelet aggregation in a dose dependant manner following 
stimulation with ADP and collagen. The concentration of agonist did not affect 
inhibition of platelets caused by cucurbitacin and the highest concentration of each 
cucurbitacin caused a decrease in overall amount of aggregation. Although no 




Figure 8: Cucurbitacins inhibit platelet aggregation with agonist collagen in PRP. Human platelet rich plasma (PRP) in 96 well plates 
were treated with increasing concentrations of cucurbitacin i) B, ii) E and iii) I (0. 0.1, 0.3, 1, 3, 10 µM) and incubated at room temperature 
for 10 minutes. Plates were shaken at 1200 rpm for 5 minutes at a temperature of 37o C following addition of increasing concentrations 
of agonist Collagen (0. 0.1, 0.3, 1, 3, 10 µg/mL). Light absorbance measured at 450 nm and converted to % light transmission and A) 
Corrected change light transmission curve in PRP. B) Inhibition curve of cucurbitacins in PRP plotted using GraphPad Prism software.  Error 
bars in graphs represent variability of the data collected to indicate any errors in experiments including variability in participants and 
potency of each blood sample to cucurbitacin and agonist.. Data expressed as mean + S.E.M for N≤5.  * indicates p<0.05 in comparison 





Figure 9: Cucurbitacin inhibits platelet aggregation with agonist collagen in WP. Human washed platelet (WP) in 96 well plates were 
treated with increasing concentrations of cucurbitacin i) B, ii) E and iii) I (0. 0.1, 0.3, 1, 3, 10 µM) and incubated at room temperature for 
10 minutes. Plates were shaken at 1200 rpm for 5 minutes at a temperature of 37oC following addition of increasing concentrations of 
agonist Collagen (0. 0.1, 0.3, 1, 3, 10 µg/mL). Light absorbance measured at 450 nm and converted to %light transmission. A) Corrected 
change light transmission curve in WP. B) Inhibition curve of cucurbitacins in WP.  Error bars in graphs represent variability of data 
collected to indicate any errors in experiments including variability in participants and potency of each blood sample to cucurbitacin and 
agonist. Concentration curves plotted using GraphPad prism. Data expressed as mean + S.E.M for N≤5.  * indicates p<0.05 in comparison 





Figure 10: Cucurbitacin inhibits platelet aggregation with agonist ADP in PRP. Human platelet rich plasma (PRP) in 96 well plates were 
treated with increasing concentrations of cucurbitacin i) B, ii) E and iii) I (0. 0.1, 0.3, 1, 3, 10 µM) and incubated at room temperature for 
10 minutes. Plates were shaken at 1200 rpm for 5 minutes at a temperature of 37oC following addition of increasing concentrations of 
agonist ADP (0. 0.1, 0.3, 1, 3, 10 µM). Light absorbance measured at 450 nm which was converted to %light transmission. A) Corrected 
change light transmission curve in PRP. B) Inhibition curve of cucurbitacins in PRP.  Error bars in graphs represent variability of data 
collected to indicate any errors in experiments including variability in participants and potency of each blood sample to cucurbitacin and 
agonist. Concentration curves plotted using GraphPad prism. Data expressed as mean + S.E.M for N≤5.  * indicates p<0.05 in comparison 





Figure 11: Cucurbitacin inhibits platelet aggregation with agonist ADP in WP. Human Washed platelet (WP) in 96 well plates were 
treated with increasing concentrations of cucurbitacin i) B, ii) E and iii) I (0. 0.1, 0.3, 1, 3, 10 µM) and incubated at room temperature for 
10 minutes. Plates were shaken at 1200 rpm for 5 minutes at a temperature of 37oC following addition of increasing concentrations of 
agonist ADP (0. 0.1, 0.3, 1, 3, 10 µM)). Light absorbance measured at 450 nm and converted to % light transmission. A) Corrected change 
light transmission curve in WP. B) Inhibition curve of cucurbitacins in WP.  Error bars in graphs represent variability of data collected to 
indicate any errors in experiments including variability in participants and potency of each blood sample to cucurbitacin and agonist. 
Concentration curves plotted using GraphPad prism. Data expressed as mean + S.E.M for N≤5.  * indicates p<0.05 in comparison to vehicle 
controls, where normalised data shown, statistics were performed prior to normalisation. Data was analysed using two-way Anova.
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4.2 Cucurbitacins inhibit real-time aggregation.  
Real time aggregation was used to analyse the effect of cucurbitacin B, E and I on the 
kinetics of platelet aggregation in response to the different platelet agonists; ADP (10 
µM) and collagen (1µg/mL ), to determine whether the cucurbitacins altered the early 
time points of aggregation in addition to overall levels of aggregation after 5 minutes 
following stimulation. As with end point aggregation, in washed platelets, 
cucurbitacin B, E and I were found to cause a concentration dependent decrease in 
platelet aggregation following stimulation with ADP (Figure 12) and collagen (Figure 
13) at 5 minutes. Interestingly aggregation was also found to be inhibited at earlier 
time points. Maximum inhibition in cucurbitacin B was attained with 10 µM at 5 
minutes (figure 12A) with stimulation with ADP 10 µM. Interestingly, aggregation was 
also inhibited at earlier time points by the cucurbitacins indicating that cucurbitacins 
delay aggregation. For example, at 2 minutes, cucurbitacin B (10µM) caused ~30% 
aggregation compared to vehicle ~35% which carried on at each time point. 
Cucurbitacin E showed similar results with 10 µM causing a ~36% aggregation 
compared to vehicle ~40%. Cucurbitacin I 1 µM showed a reduction in aggregation, 
for example at 2 minutes there was a ~37.5% aggregation compared to vehicle ~40.5% 
and was seen across each time. Similarly, stimulation with agonist collagen showed 
similar results. Cucurbitacin B (10µM) caused ~42% aggregation compared to vehicle 
~90% which carried on at each time point. Additionally, Cucurbitacin E 10µM showed 
~62% aggregation compared to vehicle ~90% at 2 minutes and cucurbitacin I 10µM 
showed aggregation to be ~35% in comparison to vehicle ~90% at 2 minutes (Figure 
13). This demonstrates that cucurbitacins delay platelet aggregation when stimulated 











Figure 12. Cucurbitacin B, E and I inhibit real time platelet aggregation with ADP.  
Human-washed platelets were pre-treated increasing concentrations of A) 
cucurbitacin B, B) cucurbitacin E or C) cucurbitacin I (0.1-10 µM) Representative traces 
shown. Tyrodes buffer with agonist and platelets used as a vehicle control to check 
that agonist was stimulating platelets. Stimulated with agonist ADP (10 µM) and 
aggregation was monitored for 5 minutes by real time optical light aggregometry. 
Data presented as % aggregation at the following time points (1, 2, 3 and 5 minutes) 
and expressed as mean + S.E.M for N≤4. * followed with bar indicates p<0.05 in 
comparison to other concentrations.  Where normalised data shown, statistics were 




Figure 13. Cucurbitacin B, E and I inhibit real time platelet aggregation with collagen.  Human-washed platelets were pre-treated 
increasing concentrations of A) cucurbitacin B, B) cucurbitacin E or C) cucurbitacin I (0.1-10 µM). Blue bars represent vehicle, orange 
represents 0.1 µM, grey represents 1 µM and yellow represents 10 µM. Tyrodes buffer with agonist and platelets used as a vehicle control 
to check that agonist was stimulating platelets. Stimulated with agonist collagen (1µg/mL) and aggregation was monitored for 5 minutes 
by real time optical light aggregometry. Data presented as % aggregation at the following time points (1, 2, 3 and 5 minutes) and 
expressed as mean + S.E.M for N≤4.  * indicates p<0.05 in comparison to vehicle controls, * followed with bar indicates p<0.05 in 
comparison to other concentrations. Where normalised data shown, statistics were performed prior to normalisation. Data was analysed 




4.3 Cucurbitacins inhibit platelet thrombus formation.  
Having observed an inhibitory effect of cucurbitacins on platelet aggregation, the 
effect of cucurbitacins on thrombus formation on collagen was evaluated in human 
whole blood under flow conditions to see whether this inhibition in aggregation 
disrupted the ability of platelets to form stable thrombi formation. Blood was 
perfused over collagen (100 μg/mL) coated vena8Fluor+ biochips at an arterial shear 
rate 20 dyn/cm2 for 10 minutes. Interestingly the fluorescence intensity remained 
similar following treatment with the cucurbitacins (10 μM) compared to vehicle. 
Fluorescence intensity is a marker of platelet adhesion indicating cucurbitacins do not 
alter the platelet ability to bind to collagen (Figure 14 C). However, fluorescence 
intensity does not distinguish between larger surface area and big stable thrombi 
which may explains the similar fluorescence between cucurbitacins and vehicle. 
Therefore, the surface area covered was also measured to determine thrombi 
generation. Compared to the vehicle, all the cucurbitacins were found to cause a 
larger surface area distribution indicating increased platelet adhesion, however larger 
aggregates were noted to have formed on vehicle treated compared to cucurbitacin 
treated samples (Figure 14 B). Observations made so far demonstrated a difference 
in thrombi morphology and platelet adhesion, indicating reduced thrombus 
formation, yet these differences were not quantifiable.  The analysis methods used so 
far were unable to detect differences between stable and unstable thrombi 
formation. Therefore, the thrombus instability index Δ Sd/ Δ T (%) (Pugh et al., 2017) 
was used to determine whether treatment with cucurbitacins altered thrombus 
stability on collagen. This index measures any moving/unstable platelets/platelet 
aggregates that do not adhere to the collagen coated chips to form a stable thrombus. 
The instability index of thrombi following treatment with all three cucurbitacins 
compared to vehicle treated controls was significantly increased, indicating that the 
platelets treated with cucurbitacins were unstable and did not have the same ability 
as vehicle treated platelets to adhere to other platelets and form stable thrombi 
(Figure 14 D). Analysis of the image sequence taken show cucurbitacin treated 
thrombi to appear ‘loose’ which detach easily from the site of adhesion. 
Representative images taken at the end of each video shows that the size of thrombus 
is similar hence the similar fluorescence intensity, but the images show the difference 
in the formation and characteristics of the thrombus. The vehicle shows a uniform 
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and stable thrombus that seems to be stuck down whereas the cucurbitacins show an 
unstable, loose formation of thrombus (Figure 14 A).  
Taken together this demonstrates that cucurbitacins reduce the ability of platelets to 
form stable thrombi.  
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Figure 14: Cucurbitacins Inhibit platelet thrombus formation. 10µM DiOC6 labelled human whole blood was treated with 10 µM of 
Cucurbitacin i) B, ii) E or iii) I or vehicle (0.1% DMSO) for 10 minutes then perfused over collagen coated vena8Fluor+ biochips at an arterial 
shear rate of 20 dyn/cm2 for 10 minutes. The channels were imaged on a Nikon A1-R confocal microscope to visualise thrombus formation 
then analysed using image J to determine surface area coverage and thrombus instability index (Δ Sd/ Δ T (%)). A) Representative images 
taken at end of each video. B) surface area coverage of cucurbitacins compared to vehicle C) Fluorescence intensity (A.U) and D) Thrombus 
instability index. Results are expressed as mean + S.E.M for n≥4.  * indicates p<0.05 in comparison to vehicle controls, where normalised 











4.4 Cucurbitacin B, E and I inhibits platelet adhesion and spreading. 
In platelets, integrins binding to their ligands such as αIIbβ3 to fibrinogen mediates 
platelet adhesion to matrix proteins. This leads to platelet adhesion, and integrin 
mediated outside-in signalling drives platelet shape change and spreading. 
Aggregation analysis indicates an inhibition of the ability of platelets to form integrin 
αIIbβ3-fibrinogen bridges, which are essential for platelet aggregation. Having 
identified a reduction in platelet aggregation and unstable thrombus formation, the 
effect of cucurbitacin on platelet adhesion and spreading was determined using 
platelet adhesion assays to ascertain whether Cucurbitacins reduce the activation of 
and signalling downstream of integrin αIIbβ3. Treatment of washed platelets with 
increasing concentrations of cucurbitacin B, E or I (0. 0.1, 0.3, 1, 3, 10 µM) (Figure 15, 
16 and 17) caused a decrease in the ability of platelets to adhere to (cell count) and 
spread (surface area) on fibrinogen (Figure 15, 16 and 17 B). For example, treatment 
of platelets with 10µM cucurbitacin B caused an over 50% decrease in the number of 
platelets adhered to fibrinogen (259 +/-66.97) compared to vehicle treated platelets 
(549+/-153). 1 µM caused a 40% reduction with (333 +/- 46.33) adhered onto 
fibrinogen. Even the lowest concentration of cucurbitacin B tested, 0.1µM was 
capable of caused a 20% reduction in adhered platelets (542+/ - 111.0) compared to 
the vehicle (Figure 15A ). Similarly, cucurbitacin’s E (Figure 16 A) and I (Figure 17 A) 
show similar results with an over 60% reduction in platelets adhering to fibrinogen at 
10µM, cucurbitacin E (133+/-84.21) compared to the vehicle treated platelets controls 
(919 +/-256.0 )  or 10µM cucurbitacin I (125+/- 59.65 ) compared to the vehicle control 
(773 +/- 256.6 ). Representative images of each concentration of Cucurbitacins 
visualises this inhibition of platelet adhesion to fibrinogen as it shows the decrease in 
the number of platelets adhered (Figure 15, 16 and 17 C). This indicates treatment 
with Cucurbitacins causes a dose dependent inhibition of platelet adhesion to 
fibrinogen, indicating a potential inhibition of integrin αIIβ3 signalling. 
In addition to platelet adhesion to fibrinogen, the effect of cucurbitacins on the ability 
of platelets to undergo cytoskeletal changes and platelet spreading, a process driven 
by integrin αIIbβ3 was also determined. Total surface area covered by platelets was 
calculated and determined by correcting for number of platelets adhered. Treatment 
of platelets with either of the cucurbitacins B, E or I resulted in a decrease in the 
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surface area coverage on fibrinogen compared to the vehicle treated platelets. The % 
surface area (total area) covered by 10 µM cucurbitacin B treated platelets on 
fibrinogen was 2.5 +/- 0.8904 % compared to vehicle treated platelets which was 
18.2+/-3.520 % (Figure 15 B). Equally, 10µM cucurbitacin E treated platelets covered 
1.7+/- 0.7279 % of surface area on fibrinogen compared to vehicle treated platelets 
covered 18.5+/- 3.884 % on fibrinogen (Figure 16 B). This was also seen following pre-
treatment with cucurbitacin I, as the % area covered by 10µM cucurbitacin I treated 
platelets was 3.2+/- 0.9740 % compared to the vehicle treated which was 19.9+/- 
2.465 % total area coverage (Figure 17 B). The representative images of phalloidin 
stained platelets treated with different concentrations of Cucurbitacins shows a 
decrease in platelet surface area coverage as concentration of cucurbitacin increases 
(Figure 15, 16 and 17 D).  
This indicates that the Cucurbitacins prevent platelet shape change and spreading via 
inhibition of integrin outside in signalling or via alteration of platelet cytoskeletal 
rearrangements, which are essential for platelet spreading, including filopodia and 











Figure 15. Cucurbitacin B inhibits platelet adhesion and spreading. Human washed platelets treated i) tyrodes buffer vehicle control, or with different 
concentrations of cucurbitacin B, ii) 0.1 µM, iii) 0.3µM, iv) 1 µM, v) 3 µM, vi) 10µM, and left to adhere and spread on Fibrinogen 100 µg/mL or BSA 
coated wells of a 96 well plate at room temperature for 1 hour. Adhered platelets were fixed and labelled with DiOC6 (A) or rhodamine conjugated 
phalloidin (B) and fluorescence images of each well were captured with 20x objective lens with CELENA S Digital Imaging System and analysed by Image 
J software. Manual correction performed to ensure all individual platelets counted and prevent counting of overlapping platelets as one. A and B) 
Representative images of DiOC6 (A) or rhodamine-phalloidin (B) stained platelets adhered on fibrinogen.  Data expressed as C) Corrected number of 
platelets adhered on fibrinogen (without non-specific binding of BSA) D) Total area covered by platelets per image Data expressed as mean + S.E.M for 
N≤5.  * followed with bar indicates p<0.05 in comparison to other concentrations. Where normalised data shown, statistics were performed prior to 
normalisation. Data was analysed using one-way Anova 
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Figure 16. Cucurbitacin E inhibits platelet adhesion and spreading. Human washed platelets treated i) tyrodes buffer vehicle control, or with different 
concentrations of cucurbitacin B, ii) 0.1 µ, iii) 0.3µM, iv) 1 µM, v) 3 µM, vi) 10µM, and left to adhere and spread on Fibrinogen 100 µg/mL or BSA coated 
wells of a 96 well plate at room temperature for 1 hour. Adhered platelets were fixed and labelled with DiOC6 (A) or rhodamine conjugated phalloidin 
(B) and fluorescence images of each well were captured with 20x objective lens with CELENA S Digital Imaging System and analysed by Image J software. 
Manual correction performed to ensure all individual platelets counted and prevent counting of overlapping platelets as one. A and B) Representative 
images of DiOC6 (A) or rhodamine-phalloidin (B) stained platelets adhered on fibrinogen.  Data expressed as C) Corrected number of platelets adhered 
on fibrinogen (without non-specific binding of BSA) D) Total area covered by platelets per image Data expressed as mean + S.E.M for N≤5.  * followed 
with bar indicates p<0.05 in comparison to other concentrations. Where normalised data shown, statistics were performed prior to normalisation. Data 
was analysed using one-way Anova 
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Figure 17. Cucurbitacin I inhibits platelet adhesion and spreading. Human washed platelets treated i) tyrodes buffer vehicle control, or with different 
concentrations of cucurbitacin B, ii) 0.1 µM, iii) 0.3µM, iv) 1 µM, v) 3 µM, vi) 10µM, and left to adhere and spread on Fibrinogen 100 µg/mL or BSA 
coated wells of a 96 well plate at room temperature for 1 hour. Adhered platelets were fixed and labelled with DiOC6 (A) or rhodamine conjugated 
phalloidin (B) and fluorescence images of each well were captured with 20x objective lens with CELENA S Digital Imaging System and analysed by Image 
J software. Manual correction performed to ensure all individual platelets counted and prevent counting of overlapping platelets as one. A and B) 
Representative images of DiOC6 (A) or rhodamine-phalloidin (B) stained platelets adhered on fibrinogen.  Data expressed as C) Corrected number of 
platelets adhered on fibrinogen (without non-specific binding of BSA) D) Total area covered by platelets per image Data expressed as mean + S.E.M for 
N≤5.  * followed with bar indicates p<0.05 in comparison to other concentrations. Where normalised data shown, statistics were performed prior to 




4.5 Cucurbitacins alter integrin αIIβ3 activation  
Taking into consideration observations made in the earlier adhesion and thrombus 
formation assays, it is clear that cucurbitacins alter and inhibit adhesion of platelets 
on fibrinogen and thrombus formation. The main mediator for adhesion and 
aggregation is the integrin αIIβ3 thus; we looked at the levels of fibrinogen binding to 
platelets via integrin αIIβ3 following stimulation with ADP (10 µM) using flow 
cytometry. Platelet rich plasma diluted with 1/10 tyrodes buffer was treated with 
increasing concentrations of cucurbitacins (0.1, 1, 10 µM) and 0.1% DMSO/tyrodes as 
a vehicle control and stimulated with ADP (10 µM). We identified that as the 
concentration of cucurbitacins increases, there was a decrease in fibrinogen binding 
to platelets indicating a decrease in integrin αIIβ3 activation as fibrinogen (Figure 18). 
The median fluorescence intensity (M.F.I) for cucurbitacin B 10 µM was ~2.968 +/- 1.4 
A.U compared to the vehicle which was ~9.016 +/- 1.8 A.U. Cucurbitacin E shows a 
similar trend in that the M.F.I for 10 µM of cucurbitacin E was ~ 2.9 +/- 1.5 A.U 
compared to vehicle of ~7.768 and 10 µM cucurbitacin I measured ~3.5 +/- 1.4 AU 
compared to the vehicle ~8.6 A.U. This supports the idea that cucurbitacins inhibits 
platelet adhesion and platelet aggregation due to a decrease in the activation of 

















Figure 18: Cucurbitacins alter integrin αIIβ3 activation. Platelet rich plasma diluted 
in 1/10 tyrodes were treated with increasing concentrations of i) cucurbitacin B, ii) 
cucurbitacin E or iii) cucurbitacin I (0.1, 1, 10µM) or vehicle control (0.1% 
DMSO/tyrodes). Samples were stimulated with ADP (10µM) and incubated with anti-
fibrinogen antibody. One sample was untreated and unstimulated. MACSQuant 
(Miltenyi Biotec MACSQuant 16) flow cytometer and analysed using FlowJo software 
to determine median fluorescence intensity.  A) Median fluorescence intensity (A.U). 
Data expressed as mean + S.E.M for N≤5.  * indicates p<0.05 in comparison to vehicle 
controls, where normalised data shown, statistics were performed prior to 













4.6 Cucurbitacin treatment increases actin polymerisation in platelets 
In addition to alteration of integrin αIIbβ3 function, another possible reason for the 
observed inhibition of shape change could be changes to actin cytoskeleton dynamics, 
which are mediated by integrin activation but have also been shown to regulate 
integrin function. Following activation, platelets undergo shape change driven by 
rearrangements of the cytoskeleton. We observed a decrease in platelet spreading 
(surface area covered) following treatment with increasing cucurbitacin B, E or I (0, 
0.1, 0.3, 1, 3, 10 µM) compared to vehicle treated control indicating that cucurbitacin 
also disrupts platelet shape change and cytoskeleton rearrangement (Figure 15, 16 
and 17 B). Published studies have identified that some cucurbitacins inhibits cell 
motility by disrupting actin dynamics, and found that treatment with cucurbitacins 
results in accumulation of actin filaments in Madin-Darby canine kidney (MDCK) and 
B16-F1 mouse melanoma cell types (Knecht et al., 2010). 
Washed platelets were treated with increasing concentrations of cucurbitacins (0.1, 
1, 10 µM) or 0.1% DMSO/tyrodes as vehicle and stained with phalloidin (Alexa-488) 
and flow cytometry was performed to measure the amount of F- actin (polymerised 
actin) per platelet. No ADP was added to stimulate the cucurbitacin treated samples, 
only with untreated platelets as a positive control. Interestingly, we found that actin 
polymerisation was drastically amplified in cucurbitacins treated platelets compared 
to the vehicle and lower concentration of the cucurbitacins even in the absence of 
platelet agonist stimulation.  
The median fluorescence intensity (M.F.I) for cucurbitacin B 10 µM was ~8.112 +/- 4 
A.U compared to the vehicle which was ~0.659 +/- 0.16 A.U (figure 19 A I). 
Cucurbitacin E shows a similar trend in that the M.F.I for 10 µM of cucurbitacin E was 
~ 5.8 +/- 1.9 A.U compared to vehicle of ~1.4 +/- 0.4 A.U (figure 19 A II)  and 10 µM 
cucurbitacin I measured ~5.9 +/- 1 AU compared to the vehicle ~0.9 +/- 0.2 A.U (figure 
19 A III). This increase is indicative of the increase of actin polymerisation, disrupting 
cytoskeleton dynamics and preventing platelet shape change. Another possible 
consequence of the actin disruption is alteration of integrin function as platelet shape 









Figure 19: Cucurbitacins increases actin polymerisation. Human washed platelets 
prepared at 8x108/mL in tyrodes HEPEs buffer were treated with increasing 
concentrations of cucurbitacins (0.1, 1, 10 µM) Cucurbitacin i) B, ii) E or iii) I or vehicle 
(0.1% DMSO). An ADP (10 µM) stimulated platelets sample was included as a positive 
control but was not used to stimulate cucurbitacin treated platelets. The samples were 
fixed with 2% paraformaldehyde and centrifuged then resuspended with BD 
Phosphoflow Perm Buffer III and left to incubate. The samples were washed and 
resuspended in tyrodes containing conjugated phalloidin (Alexa-488), flow cytometry 
was used to determine receptor surface expression of antibodies. MACSQuant 
(Miltenyi Biotec MACSQuant 16) flow cytometer and analysed using FlowJo software 
to determine median fluorescence intensity. A) Median fluorescence intensity (A.U). 
Data expressed as mean + S.E.M for N≤5. * followed with bar indicates p<0.05 in 
comparison to other concentrations. Where normalised data shown, statistics were 
performed prior to normalisation. Data was analysed using Kruskall-wallis (parametric 










4.7 Cucurbitacins increase myosin light chain phosphorylation. 
To confirm whether the cucurbitacins were causing an alteration in actin 
polymerisation, we monitored the effect of cucurbitacins B, E and I on 
phosphorylation and activation of myosin light chain, which is essential for platelet 
shape change and occurs as a result of actin polymerisation. In support of the 
observations made of increased actin polymerisation in flow cytometry, as shown in 
Figure 18 an increase in the phosphorylation of myosin light chain at Ser-19 was also 
observed following treatment with increasing concentrations 0.1, 1 and 10 µM of 
cucurbitacin B, E or I compared to the vehicle control (tyrodes buffer with 0.1% DMSO) 
(Figure 20). This increase was not found to be statistically significant, but this could 
indicate that treatment of platelets with the cucurbitacins could alter cytoskeleton 
dynamics. This further supports that the cucurbitacins increases actin polymerisation 
and its components, disrupting cytoskeleton dynamics, platelet shape change, 














Figure 20: Cucurbitacins increase myosin light chain phosphorylation.  Human 
washed platelets treated with different concentrations of B) i) cucurbitacin B, ii) 
cucurbitacin E or iii) cucurbitacin I (0.1-10 µM) or, tyrodes buffer with 0.1% DMSO as 
vehicle control and left for incubation for 10 minutes, platelets stimulated with ADP 
(10 uM) were included as a positive control. The platelets were lysed with laemelli 
buffer and heated to 90oC for 5 minutes. Lysed platelets were run on pre-cast gradient 
4-20% Tris-Bis gels, transferred onto Polyvinylidene difluoride (PVDF) membrane and 
probed overnight at 4oC using primary antibody Phospho-Myosin Light Chain 2 (Ser19). 
Anti-beta Actin antibody was used as a loading control. The proteins were detected 
using immunofluorescent secondary antibodies Goat anti-Rabbit IgG Secondary 
Antibody and Goat anti-Mouse IgG Secondary Antibody at 1;10000 for one hour and 
imaged using a Li-cor Odyssey Fc. Band intensity quantified using image J software 
and actin intensity was used to correct for equal loading. A) i) Representative blot for 
actin load in control shown. A) ii) Representative blot shown for Phospho-Myosin Light 
chain. B) Quantified Myosin light chain phosphorylation corrected for loading. The 
results are expressed as mean + S.E.M for N ≤ 4. Where normalised data shown, 





Cardiovascular disease is the leading cause of death worldwide with several risk 
factors, including diet. MI and stroke occur due to the formation of a thrombus 
following platelet activation. Anti-platelet drugs and therapies are key treatments to 
aid the prevention and treatment of thrombosis. Many anti-platelet drugs developed 
work on altering different pathways of platelet function to stop the platelets ability to 
form a thrombus. Aspirin is one of the most commonly used anti-platelet drugs to 
treat thrombosis and works by irreversibly inactivating COX-1, preventing conversion 
of arachidonic acid to TXA2. This stops the platelet from being able to produce TXA2 
a key secondary mediator of platelet activation (Awtry and Loscalzo, 2000). 
Clopidogrel is another anti-platelet drug that works differently to aspirin as it works 
by irreversibly inhibiting the ADP receptor P2Y12, blocking ADP from binding. Both of 
these drugs have shown signs of resistance in certain patients such as Gum et al (Gum 
et al., 2001) who found that among patients with cardiac arrest 5-9% were aspirin 
resistant and 23% were aspirin semi responders and Heptinstall et al (Heptinstall et 
al., 2004) who found that out of 12 patients treated with clopidogrel 4 showed 
resistance. The drugs are also associated with side effects, including gastric ulcers, 
renal failure, gastrointestinal problems, excessive bleeding and even cardiac events 
(Barrett et al., 2008). For this reason, alternative strategies are required to overcome 
these disadvantages of current anti-platelet therapies including drugs that treat 
alternative platelet activator pathways.  
Targeting integrin function and integrin signalling has allowed for successful 
development of anti-platelet drugs against thrombosis as these agents work by 
altering integrin function, a crucial step for platelet activation and function. Integrins 
are important mediators for platelet signalling pathways including both platelet 
adhesion and aggregation (Nieswandt et al., 2009). The most widely expressed 
integrin, αIIbβ3, mediates platelet adhesion through the binding to its ligand 
fibrinogen via a process called outside-in signalling following ‘inside-out’ activation. 
This allows for platelets to aggregate as these integrin-fibrinogen-integrin interactions 
act as a bridge between platelets, thus allowing for platelet aggregation to occur 
resulting in formation of a thrombus (Estevez et al., 2015). However, despite their  
successes  integrin targeted anti- platelet drugs developed to date to treat thrombotic 
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events  provide limited protection as many result in excessive bleeding (Estevez et al., 
2015). Integrin antagonists such as abciximab, eptifibatide and tirofiban have proven 
beneficial to preventing thrombosis but are associated with reduced efficacy and 
severe bleeding risk and therefore failed at clinical trial stages (Chew et al., 2001).  
Therefore, this means that new strategies for targeting integrin function could be vital 
in creating a successful efficacious anti-platelet therapy.  
Integrin driven platelet shape change is important for the activation and function of 
platelets. Resting platelets are discoid in shape with a small  surface area,  once 
activated the platelet cytoskeleton under goes considerable rearrangement and 
increases the platelet surface area by extending filipodia and forming lamellipodia, 
this supports  platelet adhesion and  aggregation (Aslan et al., 2012). Cytoskeleton 
rearrangements and the formation of filipodia and lamellipodia occurs due to actin 
turnover and polymerisation. Targeting the cytoskeleton rearrangements which 
controls stable platelet adhesion and shape change could be a vital pathway to inhibit 
platelet function in thrombosis. Subsequently, this can result in the inhibition of 
platelet function as platelets are not able to undergo shape change.  
There is increasing evidence of a link between a healthy diet and improvement in 
cardiovascular risk.  Studies that suggest that a healthy diet has a positive impact on 
cardiovascular health include the Mediterranean diet. The diet is based on increased 
consumption of fruits, whole grains, nuts, green vegetables, extra virgin olive oil with 
low intakes in red meat and sweets (de Lorgeril et al., 1999). The study found that the 
diet lowered coronary heart disease.  The suggestion that this healthy diet results in 
lowered cardiovascular risk prompted other studies to investigate individual foods in 
detail to see whether they present any properties that specifically lower 
cardiovascular risk. Many studies have researched different dietary compounds and 
have found them to have anti-platelet properties that work on different platelet 
pathways and processes (Vilahur and Badimon, 2013). Research suggests that 
polyphenols may reduce the risk of coronary heart disease (Vita, 2005). Observations 
into berries that have a high concentration of phenolic compound found that they 
have cardioprotective properties. They inhibited platelet aggregation with agonist 
ADP, lowered LDL cholesterol concentrations and decreased the total cholesterol 
(Erlund et al., 2008).  
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Our aims were to investigate cucurbitacins, which are tetracyclic triterpenoid 
compounds demonstrated to have anti-inflammatory (Jayaprakasam et al., 2003), 
anti-tumour (Kee and Hongtao, 2008) (Blaskovich et al., 2003), anti-atherosclerotic 
(Bernard and Olayinka, 2010) and anti-diabetic (Aharoni et al., 2005) activity. They are 
found in pumpkin, squash and cucumbers. Many derivates of the compound exist but 
we focussed on the most widely characterised cucurbitacin B, E and I derivatives and 
analysed the anti-platelet properties of these compounds. These compounds have 
been found to inhibit integrin function in cancer cell lines and alter actin 
polymerisation in other cell types which could be potential targets for platelet 
inhibition if similar activity is found in platelet treated cucurbitacins.  
We found that each of the three cucurbitacin derivatives, Cucurbitacin B, E and I 
inhibited ADP and collagen induced platelet aggregation in a concentration 
dependant manner with increased levels of inhibition achieved at 10µM of 
cucurbitacin B, E and I (Figures 8, 9 10 and 11). Interestingly increasing the 
concentrations of agonists were not able to overcome the inhibitory effects of the 
different cucurbitacins. As cucurbitacins showed a possible inhibition of integrin 
function in previous studies, this evidence suggests that integrin function may be 
inhibited in platelets due to the importance of integrin in platelet aggregation. 
(Touihri-Barakati et al., 2017) (Gupta and Srivastava, 2014). A study found that 
cucurbitacin B inhibited the growth of breast cancer cell lines MDA-MB-231 and 4T-1 
by inhibition of HER-2 (oncogenic receptor) - integrin signalling. They confirmed the 
interaction between HER-2 and ITGA6 and demonstrated that cucurbitacin B inhibited 
this interaction.  
Furthermore, we identified that treatment with cucurbitacin B, E or I caused an 
alteration in thrombus formation compared to vehicle treated controls (Figure 14).  
Thrombi appeared less stable and did not appear to consolidate and form tight 
interactions. As aggregation was inhibited, we wanted to see whether this resulted in 
a decrease or inhibition of thrombus formation as integrin is vital for arterial 
thrombosis (Fuster et al., 1992). Comparison of fluorescence intensity and surface 
area of following treatment with cucurbitacin B, E or I indicated either an increase in 
or no alteration in thrombus formation compared to vehicle treated control. 
However, visually the thrombi formed were markedly different. Analysis of the 
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thrombus stability index identified that the thrombi formed from cucurbitacin treated 
platelets were unstable and loose suggesting that cucurbitacins form unstable 
thrombus that do not have the ability to be constant and will loosen, signifying that 
they can dissociate from the extracellular matrix or platelet aggregate as time goes 
on.  Collagen is important for the adhesion of platelets to the vessel wall as they bind 
to integrin α2 β1  thus choosing it as an agonist to observe thrombus formation 
(Jackson and Schoenwaelder, 2003). Again, integrin function is important for 
thrombus formation as it is a consequence of the platelet aggregation. However, the 
adhesion to collagen seems unaffected as the results show the fluorescence intensity 
was similar, but the thrombi appearing unstable which suggest that the platelets are 
not able to aggregate with each other. One could propose that the integrin αIIbβ3 is 
specifically affected.  
To determine whether this inhibition of stable thrombus formation was due to a 
specific cucurbitacin mediated inhibition of integrin αIIbβ3, adhesion and spreading 
assays on fibrinogen were performed. We identified a decrease in the number of 
cucurbitacin treated platelets that adhered to fibrinogen compared to vehicle treated 
control platelets (Figure 15, 16 and 17). Again, the highest concentration of 
cucurbitacins caused more of an inhibition of platelets to adhere to fibrinogen. In 
support of these findings one study found that cucurbitacin B was able to inhibit 
integrin α5β1 mediated cell adhesion, proliferation and migration of human 
glioblastoma U87 cell line. They found that the cucurbitacins affected the adhesion of 
cells to fibronectin. This suggested that the cucurbitacins affected cell adhesion by 
inhibition of the integrin to fibronectin (Touihri-Barakati et al., 2017). This could be a 
possible explanation as to why the platelets were not able to adhere via the integrin 
αIIbβ3 to fibrinogen as they previously show that ligand-integrin complexes were 
inhibited. To further understand the effect of cucurbitacins on the integrin αIIbβ3 to 
fibrinogen, we observed the activity of the integrin by measuring the fibrinogen 
binding to platelets in cucurbitacin treated platelets and vehicle treated platelets. 
Fibrinogen bound platelets decreased as the concentration of cucurbitacins increased 
(figure 18) which again highlights that the cucurbitacins inhibits the activity of the 
integrins in platelet function.  
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In addition to an inhibition in integrin function resulting in the lack of ability for the 
platelets to aggregate and form a stable thrombus, inhibition of integrin function 
would also impact the ability of platelets to be able to adhere and spread, and 
subsequently form the stable thrombus. We observed an inhibition of platelet 
adhesion and spreading following treatment with Cucurbitacins B, E or I, indicating 
irregularity in the ability of the actin cytoskeleton to undergo rearrangement, possibly 
via alteration of actin cytoskeleton dynamics. It is also known that αIIbβ3 outside-in 
signalling leads to rearrangement of cytoskeleton that are important for platelet 
spreading. Outside-in signalling via the integrin initiates the rearrangement of actin 
cytoskeleton in platelets is regulated by actin polymerisation by increasing rigidity of 
cytoskeleton to allow platelet shape change to occur and the actin depolarisation 
which allows platelet to aggregate and spread (Bearer et al., 2002).  
Following treatment with cucurbitacins, we observed that cucurbitacin treated 
platelets lost the ability to spread compared to the vehicle control treated platelets. 
We observed a decrease in surface area coverage on fibrinogen and the average size 
of platelets following cucurbitacin treatment. This indicates that treatment with 
cucurbitacins arrested the cytoskeleton rearrangement as they were no longer able 
to spread. This points towards the irregularity in actin polymerisation as the platelets 
were not able to form the extensions - lamellipodia and filipodia which derive from 
actin polymerisation required for platelet aggregation and adhesion (Bearer et al., 
2002). This correlates with the other observations made whereby the platelets were 
not able to aggregate or adhere to fibrinogen, both processes require the cytoskeletal 
rearrangements that lead to platelet shape change.  
To see whether this inhibition of platelet spreading was due to alterations in actin 
turnover, we measured actin polymerisation in cucurbitacin treated platelets using 
phalloidin, which binds to polymerised filamentous F-actin and found that it was 
drastically increased in comparison to the vehicle (Figure 19). This was not expected 
as cucurbitacins mechanism of action thus far was an inhibitory effect, so we expected 
it to inhibit actin polymerisation rather than increase.  
Cytoskeletal actin rearrangements are regulated by myosin light chain 
phosphorylation. The phosphorylation of myosin light chain is essential for platelet 
shape change. They facilitate the binding of myosin to actin-filaments which result in 
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the contraction of the platelet and regulation of cytoskeleton rearrangements 
(Johnson et al., 2007). Activated platelets contract by making the clot rigid allowing 
for the clot shape to remain uniform. We found that similar to the observations made 
with actin polymerisation, treatment with cucurbitacins caused an increase in myosin 
light chain phosphorylation compared to vehicle treated controls (Figure 20).  
A balance between the monomeric (globular) G-actin and (filament) F-actin forms of 
actin maintain the actin cytoskeleton in platelets and platelet shape. Investigation of 
the effect of cucurbitacin treatment on the actin cytoskeleton of other cell types has 
shown contrasting effects. Some studies have found that cucurbitacins caused 
polymerisation of actin. Observations in endothelial cells indicate that cucurbitacin E 
causes unwarranted depolymerisation of F-actin such as (M. D. Duncan and Duncan, 
1997) and the loss of stress fibres. A study by Graness (Graness et al., 2006) et al , 
reported cucurbitacin I mediated  disassembly of F- actin fibres that reorganised 
rather into patches of F-actin in fibroblasts. These observations indicate cucurbitacins 
have similar effects to Cytochalasin D and other inhibitors of actin polymerisation. In 
contrast, there are several other studies suggest treatment with cucurbitacin’s cause 
an increase in actin polymerisation which are more in line with the results described 
here. One study for example demonstrated  that treatment with cucurbitacin E caused 
an increase in F-actin polymerised filaments with a decrease in G-actin observed in 
prostate carcinoma cells resulting in an accumulation of actin and morphological 
changes to the cells (K. L. Duncan et al., 1996). Similarly, another study found that 
cucurbitacin B increased F-actin polymerisation and actin aggregates in myeloid 
leukaemia cell lines (Haritunians et al., 2008). These results are similar to the findings 
observed in cells following treatment with jasplakinolide, an actin-stabilising drug. 
Treatment with Jasplakinolide has been shown to increase the formation of F-actin 
aggregates in Dictyostelium amoebae which may be due to the inability of the F-actin 
in the cells to depolymerise at a normal rate (Lee et al., 1998). Interestingly a recent 
study  investigating the effect actin polymerisation on platelet function found that 
jasplakinolide-treated platelets showed impairment to αIIbβ3 activation, inhibited 
platelet aggregation and platelet spreading, indicating increased actin polymerisation 
can negatively regulate integrin αIIbβ3 function, (Bury et al., 2016) which are similar 




In conclusion, cucurbitacin B, E and I elicit anti-platelet activity including inhibition of 
platelet aggregation, platelet adhesion and stable thrombus formation by disrupting 
actin polymerisation and turnover thereby inhibiting integrin αIIbβ3 activation (Figure 
21). This subsequently prevents the formation of integrin- fibrinogen bridges platelet 
aggregation and stable thrombus formation. It is unclear how the cucurbitacin’s alter 
actin polymerisation, more research into different aspects of actin dynamic such as 
the effect of cucurbitacins on the regulators of actin polymerisation and 
depolymerisation is required to conclude the mode of action of cucurbitacin’s in 
platelet function. Nevertheless, cucurbitacins offer a potentially exciting novel anti-















Figure 21: Cucurbitacin mechanism of action in inhibiting platelets. Following plaque 
rupture, the platelet adheres via collagen and vWF to vessel wall and activation is 
enhanced through the secretion of ADP and TXA2 which bind to their receptors on 
platelet surface. Cucurbitacins inhibit platelet function by inhibiting integrin αIIbβ3 
activity preventing platelets from aggregating and undergoing shape change. 
Cucurbitacins also disrupt actin polymerisation and platelet shape change and stable 
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8.1 Step by Step guide for platelet adhesion analysis in Image J 
 
Step 1: Open up Image J (Figure 6 A) Identify the image that needs to be analysed by 
clicking the ‘file’ drop down menu and ‘open’. 
 Step 2: Create, the threshold for image analyse by clicking the ‘image’ drop down 
(figure 6 A) and clicking on ‘adjust’ which opens another drop down menu and the 
option of threshold is there. This will open an extension tab called ‘threshold’ (Figure 
6 B).  
Step 3: The original image will change to either red and black or white and black. To 
analyse DIOC6 image, select black and white to enable comparison with the original 
monochrome image (figure 6 C). To analyse phalloidin image, select red and black to 
enable comparison with the original monochrome image.  
Step 4: The extension tab enables the background to be removed (Figure 6 D). Using 
the second bar adjust until the individual platelet’s threshold mask looks the same 
size as the platelets in the original image (Figure 6 E).  
Step 5:  Once the desired image is reached, click ‘apply’ (figure 6 D), the image should 
convert to a white background and black platelet (Figure 6 F). Exit the threshold tab.  
Step 6: Select ‘analyse’ from the drop down menu (Figure 6 A) click ‘analyse particles’ 
(Figure 6 G). This allows image j to recognise what needs to be analysed by adjusting 
the size or circularity. Select the outlines option which will identify how many platelets 
were counted and where they are on the image (figure 6 G). 
Step 7: Once finished, click ‘ok’ option and the results; a summary of the results 
(Figure 6H) and outlined/highlighted image (Figure 6 H) shows up. The data is 
expressed as the total number of platelets, the total area of the platelets and average 









8.2 Step by step guide for Δ Sd/ Δ T (%) analysis in Image J  
 
Nikon ND2 plugin for image J was used to open the ND2 video file (Figure 7A), and the 
converted into an image sequence (Figure 7B). Frames at 10 second intervals were 
analysed (Figure 7C) to enable the distinction of movement (instability index) of the 
platelets.   
Step 1: To analyse, the image sequence is converted to an 8 bit to allow for a threshold 
to be created (Figure 7D). A threshold is selected that catches all of the platelets 
adhered whilst minimising background. Threshold is kept the same across treatment 
conditions per experiment. The video is then analysed for % surface area coverage of 
the thrombus.  
Step 2: The image sequence was then further analysed to find the Δ Sd/ Δ T (%) which 
is a record of the change in surface distribution with time. To do this, the threshold 
image sequence is duplicated in ImageJ, then one slice at the end of one duplicate is 
deleted and a slice at the beginning of the other duplicate is deleted (Figure 7E).  
Step 3: Both image sequences should have the same number of frames and can now 
be subtracted by one another using the image calculator tab (Figure 7F). The 
subtracted image sequence now visualises thrombi/platelets that are 
moving/unstable, whilst anything ‘stable’/stationary is eliminated by the subtraction. 
Figure 7G is a representative of the image without subtracting the image from one 
another and with all the thrombi stuck down. Figure 7H is the subtracted video that 
has been analysed.  
Step 4: The Image is then reanalysed using ‘Analyse particles’ and surface area is 
representative of Δ Sd/ Δ T (%) which is the δ in surface distribution relative to change 
in time. 
 
 
 
 
